Dyne Therapeutics To Participate In Upcoming Investor Conferences
- 2026 Cantor Global Healthcare Conference, fireside chat on Friday, September 11, 2026 at 10:20 a.m. ET in New York, NY Morgan Stanley 24 th Annual Global Healthcare Conference, fireside chat on Monday, September 14, 2026 at 9:15 a.m. ET in New York, NY Baird 2026 Global Healthcare Conference, fireside chat on Tuesday, September 15, 2026 at 10:50 a.m. ET in New York, NY
A live webcast of each fireside chat will be available in the Investors & Media section of Dyne's website at and a replay will be accessible for 90 days.
About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at , and follow us on X, LinkedIn and Facebook.
Contacts:
Investors
Mia Tobias
...
781-317-0353
Media
Stacy Nartker
...
781-317-1938
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment